Orion Oyj has reported a shareholder notification from BlackRock under Finnish securities law, drawing attention to ownership dynamics while the Helsinki-listed pharma stock trades around EUR 70 per share.<\/p>\n
Orion Oyj has reported a new major-shareholder notification from BlackRock, putting ownership changes in the spotlight for the Helsinki-based pharmaceuticals group while its shares trade near recent highs on Nasdaq Helsinki.<\/p>\n
In a stock exchange release published on 06\/05\/2026, Orion said it had received a notification under Chapter 9 Section 10 of the Finnish Securities Markets Act regarding holdings in the company by BlackRock, Inc., one of the world’s largest asset managers, according to GlobeNewswire as of 06\/05\/2026<\/a>.<\/p>\n The filing, issued as a press release to Nasdaq Helsinki, details BlackRock’s ownership and voting rights in Orion, as required when certain thresholds are crossed or reached under Finnish law, according to Orion’s investor relations page as of 06\/05\/2026<\/a>.<\/p>\n In home-market trading, Orion’s B share closed at EUR 70.60 on Nasdaq Helsinki on 06\/05\/2026, up 2.10% or EUR 1.45 on the day, according to Investing.com as of 06\/05\/2026<\/a>.<\/p>\n As of: 05.06.2026<\/p>\n By the editorial team – specialized in equity coverage.<\/p>\n At a glanceName: OrionSector\/industry: Pharmaceuticals and life sciencesHeadquarters\/country: Espoo, FinlandCore markets: Europe and selected international marketsKey revenue drivers: Prescription medicines, generics, animal health productsHome exchange\/listing venue: Nasdaq Helsinki (ORNBV)Trading currency: EUROrion Oyj: core business model<\/p>\n Orion develops and commercializes prescription drugs and other health-care products, with revenue mainly generated from proprietary pharmaceuticals, generic medicines and animal health solutions in Finland and international markets.<\/p>\n Valuation metrics and multiples for Orion Oyj<\/p>\n With Orion’s B share closing at EUR 70.60 on Nasdaq Helsinki on 06\/05\/2026, investors continue to assess the valuation in the context of the company’s pharmaceuticals pipeline and defensive earnings profile, according to Investing.com price data as of 06\/05\/2026.<\/p>\n Market data providers indicate that the stock’s latest closing level near EUR 70 per share sits modestly above some recent trading ranges on the Helsinki market, framing how market participants may compare Orion’s multiples with those of other Nordic health-care names as of early June 2026, based on Investing.com and Nasdaq Helsinki information as of 06\/05\/2026.<\/p>\n Sentiment and reactions on Orion Oyj<\/p>\n The latest disclosure on BlackRock’s stake and the share price move on Nasdaq Helsinki are likely to feature in ongoing discussions among retail investors and market commentators following Orion Oyj.<\/p>\n YouTube<\/a>X<\/a>TikTok<\/a>Instagram<\/a><\/p>\n Conclusion<\/p>\n The latest shareholder notification concerning BlackRock’s position in Orion Oyj underscores how ownership disclosures can influence market attention on the Finnish pharmaceuticals stock.<\/p>\n At the same time, the share price around EUR 70.60 on Nasdaq Helsinki as of 06\/05\/2026 provides a reference point for how investors are currently valuing Orion Oyj within the broader Nordic health-care universe.<\/p>\n Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.<\/p>\n \t